Sotagliflozin is an orally-delivered small molecule compound that we are separately developing for the treatment of type 1 diabetes and heart failure, with additional studies in type 2 diabetes. Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney.